Screening for Radiation Sensitizers of Drosophila Checkpoint Mutants
Anti-cancer therapy is largely comprised of radiation, surgery, and chemotherapy treatments. Although a single mode of therapy can be effective in treating certain types of cancer, none presents a cure. Multi-modal therapy, the use of two or more agents in combination (e.g., radiation and chemotherapy together), shows potential for a more effective treatment of cancer. The challenge then is identifying effective therapy combinations. In this chapter, we describe the use of Drosophila as a whole animal in vivo model to screen for small molecules that effectively combine with ionizing radiation to kill checkpoint mutants preferentially over wild-type. The differential use of wild-type and checkpoint mutants has the potential to identify molecules that act in a genotype-specific manner to eradicate checkpoint mutant tissues when combined with radiation, while sparing wild-type tissues.
Key wordsDrosophila radiation checkpoint molecule library drug screen cancer
The authors thank Petros Yoon for critical reading of the manuscript and for his contribution to the screen. The work in the Su lab is supported by an NIH grant (GM087276) to T. T. Su.
- 1.Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002) Molecular Biology of the Cell, Fourth ed., Garland, New York.Google Scholar